You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 19, 2026

Details for New Drug Application (NDA): 214273


✉ Email this page to a colleague

« Back to Dashboard


NDA 214273 describes ZONISADE, which is a drug marketed by Azurity and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the ZONISADE profile page.

The generic ingredient in ZONISADE is zonisamide. There are nineteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the zonisamide profile page.
Summary for 214273
Tradename:ZONISADE
Applicant:Azurity
Ingredient:zonisamide
Patents:3
Pharmacology for NDA: 214273
Mechanism of ActionCarbonic Anhydrase Inhibitors
P-Glycoprotein Inhibitors
Physiological EffectDecreased Central Nervous System Disorganized Electrical Activity
Suppliers and Packaging for NDA: 214273
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZONISADE zonisamide SUSPENSION;ORAL 214273 NDA Azurity Pharmaceuticals, Inc. 52652-8001 52652-8001-1 1 BOTTLE in 1 CARTON (52652-8001-1) / 150 mL in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION;ORALStrength100MG/5ML
Approval Date:Jul 15, 2022TE:RLD:Yes
Patent:⤷  Get Started FreePatent Expiration:Aug 18, 2038Product Flag?Substance Flag?Delist Request?
Patented Use:A METHOD OF TREATING SEIZURES
Patent:⤷  Get Started FreePatent Expiration:Aug 18, 2038Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  Get Started FreePatent Expiration:Aug 18, 2038Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links